SCHEMBL13074221

SCHEMBL13074221

C=CC(=O)Nc1ccccc1N=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 9/20 0.52
▸ PTPN1 P18031 1/20 0.46
▸ PTPN11 Q06124 1/20 0.46
▸ F13A1 P00488 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TGM1 P22735 1/20 0.41
▸ TGM3 Q08188 1/20 0.41
▸ BTK Q06187 2/20 0.39
▸ EGFR P00533 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ GSTO1 P78417 2/20 0.38
▸ RORC P51449 1/20 0.38
▸ TEC P42680 1/20 0.37
▸ TXK P42681 1/20 0.37
▸ BMX P51813 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ ITK Q08881 1/20 0.37
▸ ERBB4 Q15303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14690416 0.87 TGM2 (0.53) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL14524451 0.84 TGM2 (0.50) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL613090 0.82 TGM2 (0.65) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL31228347 0.82 TGM2 (0.65) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL9702270 0.81 TGM2 (0.47) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL5183351 0.80 TGM2 (0.50) TGM2PTPN1PTPN11LMNAEGFR
SCHEMBL1096891 0.77 GAA (0.50) LMNAKDM4EMAPT
SCHEMBL14690089 0.77 TGM2 (0.54) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL17443378 0.76 TGM2 (0.57) TGM2PTPN1PTPN11F13A1LMNA
SCHEMBL2761954 0.76 TGM2 (0.62) TGM2PTPN1PTPN11F13A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11066399-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-07-20 — — US disclosed
US-20210139472-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-13 — — US disclosed
US-10738041-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2020-08-11 — — US disclosed
US-10364239-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2019-07-30 — — US disclosed
US-7838520-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2010-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139472-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 TGM2 406/4885PTPN1 3200/4885PTPN11 3021/4885
US-10738041-B2 Ferroportin inhibitors SLC40A1, HAMP, TFRC TGM2 240/4885PTPN1 2856/4885PTPN11 2573/4885
US-11066399-B2 Ferroportin inhibitors HAMP, SLC40A1, FTH1 TGM2 375/4885PTPN1 3591/4885PTPN11 3485/4885
US-10364239-B2 Ferroportin inhibitors HAMP, SLC40A1, HMOX1 TGM2 416/4885PTPN1 2959/4885PTPN11 2938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback